.webp&w=384&q=75){kind=logo}
Loading, please wait...
Loading, please wait...
Controllable drug release at target sites represents an important challenge in precision medicine today. With rapid advances in chemistry, materials, and biology, researchers are designing novel systems for biomedicine. Specifically, modern cleavable linker design focuses on endogenous biochemical signals. These signals include specific enzymes, pH levels, and redox species. These natural triggers allow for highly specific drug activation at the tumor site.
Furthermore, enzyme-cleavable linkers utilize proteases like cathepsin B to release cytotoxic payloads efficiently. Consequently, pH-responsive systems exploit the acidic nature of the endolysosomal compartment. This strategy ensures that the drug remains inactive during systemic circulation. Therefore, patients experience fewer side effects compared to traditional chemotherapy methods. In addition, researchers are developing dual-responsive linkers to target heterogeneous tumor environments. However, manufacturing complexity and regulatory pathways remain significant challenges for these smart systems.
Moreover, these advanced linkers are currently revolutionizing antibody-drug conjugates (ADCs) and nanocarriers. By optimizing structure-activity relationships, scientists can overcome common issues like drug resistance. Future directions involve the use of artificial intelligence to predict cleavage kinetics more accurately. This progress will eventually lead to more personalized and effective therapeutic regimens for complex diseases.
These linkers respond to specific proteases overexpressed in tumors, ensuring the payload is only released within the target tissue, which reduces systemic toxicity.
Many delivery systems use linkers that remain stable at a neutral physiological pH but degrade rapidly in the acidic environment of tumor cells or lysosomes.
Disclaimer: This content is for informational and educational purposes only. It does not constitute medical advice or establish a doctor-patient relationship. Refer to the latest local and national guidelines for clinical practice.
References
Li E et al. Endogenous stimuli-responsive intelligent drug delivery systems: recent advances in cleavable linker design. Chem Commun (Camb). 2026 Apr 23. doi: 10.1039/d6cc00388e. PMID: 42023486.
Lu Yang et al. Recent Advances in Peptide Linkers of Antibody-Drug Conjugates. J Med Chem. 2025 Sep 11;68(17):18099-18113. doi: 10.1021/acs.jmedchem.5c01500.
Shaoting Li et al. Recent Advances in Peptide Linkers for Antibody-Drug Conjugates. J Med Chem. 2025 Oct 9;68(19):19871-19892. doi: 10.1021/acs.jmedchem.5c01982.
"
Read summarized clinical updates, watch expert medical content, and earn CME certifications right from your smartphone.
Open your smartphone camera to scan and install.
Discover how the latest cleavable linker designs utilize endogenous signals like pH and enzymes to enhance targeted drug delivery in oncology and pharmacy....
4 months ago
A large NHANES cohort study reveals that higher Healthy Eating Index scores significantly reduce all-cause mortality risk in CKD patients by 45%. This analysis highlights the importance of comprehensive diet quality and medical nutrition therapy in renal care to optimize long-term clinical survival.
Today
Explore real-world data showing how private oncogenetics and molecular tumor boards achieve 3-week consult turnaround, high ctDNA actionability, and vital germline variant detection, enhancing individualized cancer care and familial risk assessment.
Today
A meta-analysis of 13 propensity score-matched studies shows ViV-TAVR delivers lower early mortality and reduced bleeding compared to redo-SAVR for degenerated bioprosthetic aortic valves, though long-term hemodynamics warrant careful anatomical and patient-centered evaluation.
Today
Endoscopic posterior cervical fusion combines minimally invasive decompression, joint preparation, and rigid screw-rod fixation for atlantoaxial pathologies. Early clinical findings demonstrate solid bony union, excellent symptom relief, and minimal soft-tissue morbidity without significant vascular compromise.
Today
The All-India Food Processors' Association has approached the Supreme Court to oppose FSSAI's proposed per-100g benchmark for front-of-pack warning labels, advocating instead for a per-serving threshold. We explore the regulatory showdown, nutritional evidence, and implications for clinical lifestyle counseling.
Today
